BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21216463)

  • 21. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.
    Tirado OM; Mateo-Lozano S; Notario V
    Oncogene; 2005 May; 24(20):3348-57. PubMed ID: 15782132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2-Methoxyestradiol blocks cell-cycle progression at the G2/M phase and induces apoptosis in human acute T lymphoblastic leukemia CEM cells.
    Zhang X; Huang H; Xu Z; Zhan R
    Acta Biochim Biophys Sin (Shanghai); 2010 Sep; 42(9):615-22. PubMed ID: 20732853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
    Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
    Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1.
    Polier G; Ding J; Konkimalla BV; Eick D; Ribeiro N; Köhler R; Giaisi M; Efferth T; Desaubry L; Krammer PH; Li-Weber M
    Cell Death Dis; 2011 Jul; 2(7):e182. PubMed ID: 21776020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular mechanisms of anti-tumor properties of P276-00 in head and neck squamous cell carcinoma.
    Mishra PB; Lobo AS; Joshi KS; Rathos MJ; Kumar GA; Padigaru M
    J Transl Med; 2013 Feb; 11():42. PubMed ID: 23414419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways.
    Zhang YW; Jiang XX; Chen QS; Shi WY; Wang L; Sun HD; Shen ZX; Chen Z; Chen SJ; Zhao WL
    Exp Hematol; 2010 Mar; 38(3):191-201. PubMed ID: 20045442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
    Gao N; Kramer L; Rahmani M; Dent P; Grant S
    Mol Pharmacol; 2006 Aug; 70(2):645-55. PubMed ID: 16672643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
    Zi FM; He JS; Li Y; Wu C; Yang L; Yang Y; Wang LJ; He DH; Zhao Y; Wu WJ; Zheng GF; Han XY; Huang H; Yi Q; Cai Z
    Cancer Lett; 2015 Jan; 356(2 Pt B):443-53. PubMed ID: 25305450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest.
    Datta NS; Chen C; Berry JE; McCauley LK
    J Bone Miner Res; 2005 Jun; 20(6):1051-64. PubMed ID: 15883646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
    Evans RP; Naber C; Steffler T; Checkland T; Maxwell CA; Keats JJ; Belch AR; Pilarski LM; Lai R; Reiman T
    Br J Haematol; 2008 Feb; 140(3):295-302. PubMed ID: 18076711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.
    Lim SL; Xu L; Han BC; Shyamsunder P; Chng WJ; Koeffler HP
    PLoS One; 2020; 15(6):e0232068. PubMed ID: 32559187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers.
    Rathos MJ; Joshi K; Khanwalkar H; Manohar SM; Joshi KS
    J Transl Med; 2012 Aug; 10():161. PubMed ID: 22873289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
    Santo L; Vallet S; Hideshima T; Cirstea D; Ikeda H; Pozzi S; Patel K; Okawa Y; Gorgun G; Perrone G; Calabrese E; Yule M; Squires M; Ladetto M; Boccadoro M; Richardson PG; Munshi NC; Anderson KC; Raje N
    Oncogene; 2010 Apr; 29(16):2325-36. PubMed ID: 20101221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.
    Hui AB; Yue S; Shi W; Alajez NM; Ito E; Green SR; Frame S; O'Sullivan B; Liu FF
    Clin Cancer Res; 2009 Jun; 15(11):3716-24. PubMed ID: 19470731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
    Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
    Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.
    Baughn LB; Di Liberto M; Wu K; Toogood PL; Louie T; Gottschalk R; Niesvizky R; Cho H; Ely S; Moore MA; Chen-Kiang S
    Cancer Res; 2006 Aug; 66(15):7661-7. PubMed ID: 16885367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells.
    Rathos MJ; Khanwalkar H; Joshi K; Manohar SM; Joshi KS
    BMC Cancer; 2013 Jan; 13():29. PubMed ID: 23343191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.
    Caracciolo V; Laurenti G; Romano G; Carnevale V; Cimini AM; Crozier-Fitzgerald C; Gentile Warschauer E; Russo G; Giordano A
    Cell Cycle; 2012 Mar; 11(6):1202-16. PubMed ID: 22391209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.